Axogen Shares Hit 52-Week High After Swing to Profit, Lifted FY Guide

Dow Jones

Oct 30, 2025

By Chris Wack and Katherine Hamilton

Axogen shares jumped after the company swung to a profit and raised its full-year outlook.

Axogen shares were up 25% at $22.65, at one point reaching a 52-week high of $22.95. The stock has gained 62% in the past 12 months.

The provider of surgical services for nerve repair on Wednesday posted a profit of $708 million, or 1 cent a share, compared with a loss of $1.86 billion, or 4 cents a share, the year before. Analysts polled by FactSet were looking for a loss of $1.4 million, or 3 cents a share.

Adjusted earnings were 12 cents a share, compared with the 7 cents a share analysts had forecast.

Revenue for the quarter was $60.1 million, up about 24% from last year's $48.6 million. Analysts were expecting $56.9 million.

Axogen said its third-quarter revenue growth was broad-based with double-digit growth in all markets, including extremities, oral maxillofacial and head and neck, and breast.

Axogen now expects 2025 revenue to grow at least 19% to $222.8 million, up from its previous guidance of $219 million. The Alachua, Fla., company also expects to be net cash flow positive for the full year.

Write to Chris Wack at chris.wack@wsj.com and Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

October 29, 2025 14:04 ET (18:04 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2579605184"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579605184\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579605184?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-30 02:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579605184","market":"us","top_or_hot":-1,"title":"Axogen Shares Hit 52-Week High After Swing to Profit, Lifted FY Guide","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Chris Wack and Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Axogen shares jumped after the company swung to a profit and raised its full-year outlook. \n</p>\n<p>\n  Axogen shares were up 25% at $22.65, at one point reaching a 52-week high of $22.95. The stock has gained 62% in the past 12 months. \n</p>\n<p>\n  The provider of surgical services for nerve repair on Wednesday posted a profit of $708 million, or 1 cent a share, compared with a loss of $1.86 billion, or 4 cents a share, the year before. Analysts polled by FactSet were looking for a loss of $1.4 million, or 3 cents a share. \n</p>\n<p>\n  Adjusted earnings were 12 cents a share, compared with the 7 cents a share analysts had forecast. \n</p>\n<p>\n  Revenue for the quarter was $60.1 million, up about 24% from last year's $48.6 million. Analysts were expecting $56.9 million. \n</p>\n<p>\n  Axogen said its third-quarter revenue growth was broad-based with double-digit growth in all markets, including extremities, oral maxillofacial and head and neck, and breast. \n</p>\n<p>\n  Axogen now expects 2025 revenue to grow at least 19% to $222.8 million, up from its previous guidance of $219 million. The Alachua, Fla., company also expects to be net cash flow positive for the full year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com and Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 29, 2025 14:04 ET (18:04 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Axogen Shares Hit 52-Week High After Swing to Profit, Lifted FY Guide</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAxogen Shares Hit 52-Week High After Swing to Profit, Lifted FY Guide\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-30 02:04</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Chris Wack and Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Axogen shares jumped after the company swung to a profit and raised its full-year outlook. \n</p>\n<p>\n  Axogen shares were up 25% at $22.65, at one point reaching a 52-week high of $22.95. The stock has gained 62% in the past 12 months. \n</p>\n<p>\n  The provider of surgical services for nerve repair on Wednesday posted a profit of $708 million, or 1 cent a share, compared with a loss of $1.86 billion, or 4 cents a share, the year before. Analysts polled by FactSet were looking for a loss of $1.4 million, or 3 cents a share. \n</p>\n<p>\n  Adjusted earnings were 12 cents a share, compared with the 7 cents a share analysts had forecast. \n</p>\n<p>\n  Revenue for the quarter was $60.1 million, up about 24% from last year's $48.6 million. Analysts were expecting $56.9 million. \n</p>\n<p>\n  Axogen said its third-quarter revenue growth was broad-based with double-digit growth in all markets, including extremities, oral maxillofacial and head and neck, and breast. \n</p>\n<p>\n  Axogen now expects 2025 revenue to grow at least 19% to $222.8 million, up from its previous guidance of $219 million. The Alachua, Fla., company also expects to be net cash flow positive for the full year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com and Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 29, 2025 14:04 ET (18:04 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2579605184","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579605184","pubTimestamp":1761761040,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Axogen shares jumped after the company swung to a profit and raised its full-year outlook.Axogen shares were up 25% at $22.65, at one point reaching a 52-week high of $22.95. The stock has gained 62% in the past 12 months.The provider of surgical services for nerve repair on Wednesday posted a profit of $708 million, or 1 cent a share, compared with a loss of $1.86 billion, or 4 cents a share, the year before. Analysts polled by FactSet were looking for a loss of $1.4 million, or 3 cents a share.Adjusted earnings were 12 cents a share, compared with the 7 cents a share analysts had forecast.Revenue for the quarter was $60.1 million, up about 24% from last year's $48.6 million. Analysts were expecting $56.9 million.Axogen said its third-quarter revenue growth was broad-based with double-digit growth in all markets, including extremities, oral maxillofacial and head and neck, and breast.Axogen now expects 2025 revenue to grow at least 19% to $222.8 million, up from its previous guidance ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","AXGN":"AxoGen Inc."},"translate_title":"Axogen股价在扭亏为盈并上调财年指引后触及52周高点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AXGN":1.5},"content_text":"By Chris Wack and Katherine Hamilton \n\n\n \n\n\n  Axogen shares jumped after the company swung to a profit and raised its full-year outlook. \n\n\n  Axogen shares were up 25% at $22.65, at one point reaching a 52-week high of $22.95. The stock has gained 62% in the past 12 months. \n\n\n  The provider of surgical services for nerve repair on Wednesday posted a profit of $708 million, or 1 cent a share, compared with a loss of $1.86 billion, or 4 cents a share, the year before. Analysts polled by FactSet were looking for a loss of $1.4 million, or 3 cents a share. \n\n\n  Adjusted earnings were 12 cents a share, compared with the 7 cents a share analysts had forecast. \n\n\n  Revenue for the quarter was $60.1 million, up about 24% from last year's $48.6 million. Analysts were expecting $56.9 million. \n\n\n  Axogen said its third-quarter revenue growth was broad-based with double-digit growth in all markets, including extremities, oral maxillofacial and head and neck, and breast. \n\n\n  Axogen now expects 2025 revenue to grow at least 19% to $222.8 million, up from its previous guidance of $219 million. The Alachua, Fla., company also expects to be net cash flow positive for the full year. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com and Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 29, 2025 14:04 ET (18:04 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}